Introduction: Clostridium difficile infection (CDI) is the most common cause of
Overall mortality rates within the follow-up period of 1 year were 13.5% in inpatients with primary diagnosis of CDI, compared to 24 
INTRODUCTION
Clostridium difficile infection (CDI) is the most common cause of health-care-associated infectious diarrhea, affecting primarily elderly patients ([65 years) with comorbidities and exposure to antibiotics [1] [2] [3] [4] [5] . At least 7-17% of adult hospitalized patients are colonized by C.
difficile, with higher rates observed in elderly long-term patients [4, 6] . C. difficile is also responsible for diarrheal diseases in patients with no risk factors (community-acquired CDI) [1, 5, 7] , and is associated with zoonotic transmission, particularly PCR-ribotype 078 [8, 9] . Highly virulent C. difficile strains have emerged since 2003 leading to a predominance of PCR-ribotype 027 in many hospitals of North America and Europe. This development is made responsible for increased severity of illness and increased mortality [1-5, 7, 10, 11] . In Canada, a cumulative attributable mortality of 16.7% was demonstrated for CDI patients after the arrival of PCR-ribotype 027 [11] . Each case of nosocomial CDI led, on average, to 10.7 additional days in hospital [11] . In a Dutch case-control study, the highest mortality was also seen among very elderly patients and patients with PCR-ribotype 027 [12] . The occurrence of CDI was associated with a 2.5-fold increase in 30-day mortality compared to controls without diarrhea when adjusted for age, sex, and underlying diseases.
CDI-related death occurred mainly within 30 days after diagnosis [12] .
Recurrence rates of CDI given in the literature are as high as 20-30% after standard treatment with metronidazole or vancomycin [13] , and appear to be reduced for patients treated with fidaxomicin [14] [15] [16] , which became available for treatment of CDI in Germany at the end of 2012. According to Surawicz and other authors, the risk of CDI recurrence increases after the second relapse to 30-65% [17, 18] . The current overall economic burden per CDI, addressed as direct treatment costs, has been reported to reach between €7147 and €22,800 [19] [20] [21] . However, CDI recurrence is particularly associated with excessive costs, which are mostly attributable to a significantly longer overall length of hospital stay [22] . In a for this database allowing to analyze high granular health data and insurance biographies over several years. With coverage of patients from all parts of the country, the population investigated seems to be fairly representative for the whole German population.
METHODS

Study Population and Data Analysis
Based on the research database of arvato health analytics (Munich, Germany), a secondary data analysis for the incidence, recurrence and course of CDI was performed. The database used for this purpose included high granular accounting All CDI patients were followed-up for 1 year from the index event or until death. New CDI cases were meticulously analyzed as to whether and how often a recurrence occurred, defined as re-encoding of the ICD-10 code A04.7, or outpatient diagnosis in conjunction with CDI-related medication, within 11-60 days of follow-up. Events within 0-10 days of follow-up were not counted as recurrences, because standard CDI drug therapy extends for 10 days. Thus, encoding of a later CDI event (C60 days) was counted as a new index event.
Events during hospitalization were further distinguished according to primary or secondary diagnosis of CDI. Accordingly, the length of hospital stay (LOS) refers to the overall LOS and not the LOS attributed to CDI.
Statistical Analysis
Statistical analysis was performed using SPSS for Windows (SPSS 20.0; IBM, Armonk, New York, USA). Numerical variables were summarized as median, and categorical variables were given as frequencies or proportions. Categorical data were analyzed by the Chi square test or Fisher's exact test. For comparison of two independent groups, the nonparametric Mann-Whitney U test was used. P values (2-sided) of\0.05 were considered statistically significant.
Ethics Compliance
This retrospective study was performed in accordance with the ethical guidelines of the 1964 Declaration of Helsinki and its later amendments.
For this type of study, formal consent is not required in accordance with the federal legislation of the Free State of Saxony, Germany. As the study did not modify patient management and the data were processed anonymously, the need for informed consent was waived. An extrapolation of this sample to other statutory and private health insurances in Germany is given in the righthand column 38.1%, the LOS varied from 10 to 19 days.
RESULTS
Longer hospital stays were rather rare. Patients with a secondary diagnosis of CDI remained significantly longer in the hospital (median 24 days, P\0.001) (Fig. 1) . A total of 13.5% of inpatients with primary diagnosis of CDI (index events) died within the follow-up period of 1 year, compared to 24.3% with secondary diagnosis of CDI (P = 0.018). By contrast, in the outpatient setting, only 7.1% of CDI patients (index events) died within 1 year after the diagnosis was encoded, revealing a significant difference compared with inpatients with primary diagnosis of CDI (P\0.001). The overall mortality rates increased significantly from index event to second recurrence of CDI (Fig. 2) . Germany) [25] . The increased inpatient mortality rates are strongly associated with a high probability of increased comorbidity, especially in patients with CDI as secondary diagnosis.
According to various publications, 20-30% of CDI patients suffer a recurrence after initial treatment [13] [14] [15] [16] 26] , which is consistent with our results and shows that this trend is at least as high as previously assumed. According to Surawicz and other authors, the risk of CDI recurrence after the second relapse increases to 30-65% [17, 18, 25] . This estimate could not be reproduced in our analysis (recurrence of CDI was observed in 18.2% of the cases, and there was a significant increase in the frequency of a second and third recurrence, reaching 28.4% and 30.2%, respectively). However, it was generally confirmed that there is a steadily increasing risk after each relapse for ongoing recurrence, which is associated with a significant increase in overall mortality Fig. 2 One-year mortality rates of study patients depending on the recurrence of CDI (Fig. 2) , as previously pointed out in a European study by Bauer and colleagues [1] . According to their findings, 40% of all deaths may be attributed directly to CDI.
Our data include evaluation of antibiotic treatment characteristics which reflect that success rates of standard CDI therapies (metronidazole and vancomycin) are limited by (1) their non-guideline compliant use [26] with a high proportion of metronidazole therapy even for the second recurrence (43.5%), and (2) their broad spectrum activity causing considerable perturbation of the intestinal microbiota [27] . Besides novel therapeutic strategies with antibiotics with a narrow spectrum of activity targeted strictly against C. difficile showing a diminished impact and damage on the anaerobic flora of the gastrointestinal tract such as fidaxomicin [14, 15, 27] , further innovative therapeutic strategies for CDI are urgently needed.
Limitations
Regarding interpretation of our results, the general limitations of a claims data-based analysis have to be considered. Our analysis largely depends on the quality of medical coding, which particularly relies on given clinical and diagnostic information, e.g., microbiological data and medication.
Secondary data contain only information on services that are relevant for reimbursement. Coding of claims may be subject to incentives for reporting. Moreover, one has to consider that outpatient diagnoses of recurrent CDI without CDI-specific therapy within the same quarter could not be detected in the dataset.
Inpatient diagnoses of recurrent CDI include only patients being discharged between the index date and first recurrence, or between first and second recurrence. Therefore, a recurrence of CDI within the same hospitalization period could not be tracked, which could have led to a false low recurrence rate in inpatients. To estimate the maximum number of recurrences within one hospital stay, the proportion of stays longer than 25 days was stated. Although recurrences were tracked starting from day 11 after the index date (assuming 10 days of standard therapy), a lack of differentiation regarding prolonged treatment of initial CDI and treatment of a genuine relapse remains.
Regarding the assessment of mortality rates, our analysis is weakened by missing clinical information on the severity of CDI events. 
